archetype (adl_version=2.3; rm_release=0.0.1)
  SHR-CORE-EstrogenReceptorStatus.estrogen_receptor_status.v0.0.1

specialize
  SHR-CORE-SimplifiedLaboratoryTestResultRecorded.simplified_laboratory_test_result_recorded.v0.0.1

language
  original_language = <[ISO_639-1::en]>

description
  original_author = <
    ["name"] = <"Mark Kramer">
    ["organisation"] = <"The MITRE Corporation">
    ["email"] = <"mkramer@mitre.org">
    ["date"] = <"5/8/2018">
  >
  details = <
    ["en"] = <
      language = <[ISO_639-1::en]>
      purpose = <"SHR implementation of ASCO requirements.">
      use = <"SHR implementation of ASCO requirements.">
      keywords = <"oncology","estrogen receptor status">
    >
  >
  lifecycle_state = <"initial">
  other_contributors = <"Rute Batiste <rbatiste@mitre.org>, Chris Moesel <cmoesel@mitre.org>, Abhijay Bhatnagar <abhatnagar@mitre.org>, Michael O'Keefe <mokeefe@mitre.org>">
  custodian_organisation = <"The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC).">
  licence = <"Creative Commons CC-BY <https://creativecommons.org/licenses/by/3.0/>">
  copyright = <"Copyright (c) The MITRE Organization <http://mitre.org>">

definition
  EstrogenReceptorStatus[id1.1.1.1.1.1.1.1] matches {
   -- topicCode matches {
    --  CodeableConcept = <[http://loinc.org::16112-5]>
    -- }
    specimen matches {
      BreastSpecimen[id0.0.0.0.0.0.0.3]
    }
    /interpretation/value matches {[ac0.0.0.0.0.0.0.1]}

   -- /diagnosticService/value matches  <[http://hl7.org/fhir/us/breastcancer/finding/cs/DiagnosticServiceCS::pathology]>
    /valueChoiceRange matches {
      PercentageRange[id0.0.0.0.0.0.0.4]
    }
  }

terminology
  term_definitions = <
    ["en"] = <
      ["id1.1.1.1.1.1.1.1"] = <
        text = <"EstrogenReceptorStatus">
        description = <"Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options.

                      We are seeking feedback if it is better to put the positive/negative status in Value or Interpretation. The point of view expressed in this model is that positive/negative designation is an interpretation, based on evidence such as NuclearPositivity and AverageStainingIntensity, not a direct result. This also appears to be the most consistent approach across all receptor statuses (ER, PR, and HER2).">
      >
      ["id0.0.0.0.0.0.0.2"] = <
        text = <"CodeableConcept">
        description = <"A set of codes drawn from different coding systems, representing the same concept.">
      >
      ["id0.0.0.0.0.0.0.3"] = <
        text = <"BreastSpecimen">
        description = <"Specimen resulting from biopsy or excision of breast and surrounding tissue.">
      >
      ["id0.0.0.0.0.0.0.4"] = <
        text = <"PercentageRange">
        description = <"A range of percentage values.">
      >
      ["ac0.0.0.0.0.0.0.1"] = <
        text = <"http://hl7.org/fhir/us/breastcancer/oncology/vs/PositiveNegativeVS">
        description = <"-">
      >
      ["at0.0.0.0.0.0.0.1"] = <
        text = <"16112-5">
        description = <"-">
      >
      ["at0.0.0.0.0.0.0.2"] = <
        text = <"pathology">
        description = <"-">
      >
    >
  >
  term_bindings = <
    ["snomed-ct"] = <
      items = <
      --   ["id0.0.0.0.0.0.0.1"] = <16112-5>
      >
    >
    ["shr"] = <
      items = <
     -- ["id0.0.0.0.0.0.0.2"] = <http://hl7.org/fhir/us/breastcancer/oncology/vs/PositiveNegativeVS>
     -- ["id0.0.0.0.0.0.0.3"] = <pathology>
      >
    >
  >